Three-Year Prospective Menstrual and Dysmenorrhea Outcomes after Thermachoicelll? in-Office Therapy

摘要

THE FIRST GLOBAL ENDOMETRIAL ABLATION DEVICE in clinical use was the Gynecare Thermachoice? Uterine Balloon Therapy System introduced in 1997. Despite well-published historic data on the safety and efficacy of Thermal Balloon Ablation (TBA),1'2 a MEDLINE? and PubMed search a paucity of peer review published data on long term outcomes from use of the TBA method currently in clinical use (Gynecare ThermachoiceHI? Uterine Balloon Therapy System Gynecare, Ethicon, Somerville, NJ). Traditionally, with first generation TBA, therapy success was defined as the percentage of patients with normal or no bleeding at 3 years and without hysterectomy or repeat ablation throughout the 3 years of "long-term" follow-up.3 Gervaise et al. reported a cumulative 3-year success rate, defined as eumenorrhea or less, of 83% for first-generation uterine balloon therapy and 76% for endometrial resection.4